188 related articles for article (PubMed ID: 32959428)
21. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
22. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
23. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
[TBL] [Abstract][Full Text] [Related]
24. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.
Mongiorgi S; Follo MY; Yang YR; Ratti S; Manzoli L; McCubrey JA; Billi AM; Suh PG; Cocco L
Curr Pharm Des; 2016; 22(16):2345-8. PubMed ID: 26916022
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
26. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
27. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
28. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
Guariglia R; Martorelli MC; Villani O; Pietrantuono G; Mansueto G; D'Auria F; Grieco V; Bianchino G; Lerose R; Bochicchio GB; Musto P
Leuk Res; 2011 May; 35(5):566-70. PubMed ID: 21185078
[TBL] [Abstract][Full Text] [Related]
29. PI-PLCβ1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress.
Piazzi M; Blalock WL; Bavelloni A; Faenza I; Raffini M; Tagliavini F; Manzoli L; Cocco L
FASEB J; 2015 Apr; 29(4):1383-94. PubMed ID: 25550457
[TBL] [Abstract][Full Text] [Related]
30. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
31. Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex.
O'Carroll SJ; Mitchell MD; Faenza I; Cocco L; Gilmour RS
Cell Signal; 2009 Jun; 21(6):926-35. PubMed ID: 19385066
[TBL] [Abstract][Full Text] [Related]
32. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
[TBL] [Abstract][Full Text] [Related]
33. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
34. Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia.
Ratti S; Mongiorgi S; Rusciano I; Manzoli L; Follo MY
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118649. PubMed ID: 31954103
[TBL] [Abstract][Full Text] [Related]
35. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
[TBL] [Abstract][Full Text] [Related]
36. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
37. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
39. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
Zeidan AM; Hendrick F; Friedmann E; Baer MR; Gore SD; Sasane M; Paley C; Davidoff AJ
J Comp Eff Res; 2015 Aug; 4(4):327-40. PubMed ID: 26274794
[TBL] [Abstract][Full Text] [Related]
40. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
